PMID: 7546914Jul 1, 1995Paper

Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells

AIDS Research and Human Retroviruses
F F WeicholdR C Gallo

Abstract

The use of antisense oligodeoxynucleotides as antiviral drugs to combat HIV-1 infection may offer an alternative to traditional pharmacological therapies. We compared the effects of two 28-mer antisense phosphorothioate oligodeoxynucleotides [PS-oligo(dN)] with non-sequence-specific controls on HIV-1 replication in long-term human monocyte/macrophage and PBMC cultures. The anti-rev PS-oligo(dN) was complementary to the messenger RNA (mRNA) sequences derived from the overlapping region of the HIV-1 regulatory genes tat and rev, while anti-gag targeted the translational initiation site of the gag mRNA. In vitro cytotoxicity of the PS-oligo(dN) was evaluated at concentrations ranging from 0.1 to 10.0 microM for a period of 20 days. Cell survival was 100% at 0.1 microM, but decreased to 5% at 10.0 microM in relation to the untreated control cultures. Our data demonstrate that replication of both the T cell-tropic and macrophage-tropic HIV-1 strains in primary cells can be inhibited by PS-oligo(dN) in a sequence-specific and dose-dependent manner at concentrations achievable in vivo. However, the sequence-dependent antiviral activity of the utilized PS-oligo(dN) was limited to a window of specificity at concentrations between 0.25 a...Continue Reading

References

Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·P C Zamecnik, M L Stephenson
Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T M WoolfC G Jennings
Dec 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J LisziewiczR Gallo
Aug 1, 1988·Journal of Virological Methods·R PauwelsE De Clercq
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalP C Zamecnik
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R Y Walder, J A Walder
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P C ZamecnikP S Sarin
Jul 11, 1986·Science·S GartnerM Popovic
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J GoodchildP C Zamecnik
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalP C Zamecnik
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·P S SarinP C Zamecnik
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·M MatsukuraS Broder
Apr 1, 1993·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S T Crooke
Aug 16, 1994·Proceedings of the National Academy of Sciences of the United States of America·J LisziewiczS Agrawal
May 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J LisziewiczS Agrawal
May 25, 1993·Biochemical Pharmacology·R F BrandaG Zon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.